Burden of Psoriasis as Reported in a Cross-Sectional Study: Association of Psoriasis Severity with Health-Related Quality of Life,Depression,and Work Productivity

Abstract

Background

A significant gap exists in how psoriasis severity is related to validated patient-reported outcomes (PROs), which are critical in characterizing disease burden.

Objective

Determine the association between psoriasis severity and PROs, including health-related quality of life (HRQoL), depression, and work productivity, from patients’ perspectives.

Methods

An online survey using validated PRO instruments was administered in 2013. PROs included the Dermatology Life Quality Index, Quick Inventory of Depressive Symptoms-Self-Report (16 items) (QIDS-SR16), and Work Productivity and Activity Impairment Questionnaire-Psoriasis.

Results

The survey was completed by 1109 patients, 42% of whom had psoriatic arthritis. Respondents reported worse HRQoL and work productivity impairment with greater psoriasis severity (p < 0.05). Similarly, there was a greater proportion of participants with moderate-or-greater depressive symptoms (QIDS-SR16 total score) among patients with increasing psoriasis severity (p < 0.05).

Conclusion

Greater levels of impairment in HRQoL, work productivity, and depressive symptoms were associated with increased psoriasis severity.

Keywords

psoriasis quality of life patient burden patient-reported outcomes depressive symptoms work productivity

Get full access to this article

View all access options for this article.

References

Rachakonda

T.D.

Schupp

C.W.

Armstrong

A.W.

. Psoriasis prevalence among adults in the United States. J Am Acad Dermatol. 2014; 70(3): 512–6.

Greaves

M.W.

Weinstein

G.D.

. Treatment of Psoriasis. N Engl J Med. 1995; 332(9): 581–9.

Christophers

. Psoriasis - epidemiology and clinical spectrum. Clin Exp Dermatol. 2001; 26(4): 314–20.

Feldman

Malakouti

Koo

J.Y.M.

. Social impact of the burden of psoriasis: effects on patients and practice. Dermatol Online J. 2014; 20(8).

Armstrong

A.W.

. A Review of Health Outcomes in Patients with Psoriasis. Dermatol Clin. 2012; 30(1): 61–72.

Armstrong

A.W.

Robertson

A.D.

Schupp

Lebwohl

M.G.

. Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the united states: Findings from the national psoriasis foundation surveys, 2003-2011. JAMA Dermatol. 2013; 149(10): 1180–5.

Mrowietz

Kragballe

Reich

Definition of treatment goals for moderate to severe psoriasis: a European consensus.

Arch Dermatol Res. 2011; 303(1): 1–10.

Reich

Mrowietz

. Treatment goals in psoriasis. J Dtsch Dermatol Ges. 2007; 5(7): 566–74.

U.S. Department of Health and Human Services.

Guidance for Industry Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims 2009. (Accessed 3-Aug-2017, at https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf.)

10.

Langley

R.G.

Feldman

S.R.

Han

Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial.

J Am Acad Dermatol. 2010; 63(3): 457–65.

11.

Reich

Schenkel

Zhao

Ustekinumab decreases work limitations, improves work productivity, and reduces work days missed in patients with moderate-to-severe psoriasis: Results from PHOENIX 2.

J Dermatolog Treat. 2011; 22(6): 337–47.

12.

Revicki

D.A.

Willian

M.K.

Menter

Impact of adalimumab treatment on patient-reported outcomes: Results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis.

J Dermatolog Treat. 2007; 18(6): 341–50.

13.

Finlay

A.Y.

Khan

G.K.

. Dermatology Life Quality Index (DLQI) — a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994; 19(3): 210–6.

14.

Basra

M.K.A.

Fenech

Gatt

R.M.

Salek

M.S.

Finlay

A.Y.

. The Dermatology Life Quality Index 1994-2007: a comprehensive review of validation data and clinical results. Br J Dermatol. 2008; 159(5): 997–1035.

15.

Rush

A.J.

Trivedi

M.H.

Ibrahim

H.M.

The 16-Item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression.

Biol Psychiatry. 2003; 54(5): 573–83.

16.

AP Association. Diagnostic and statistical manual of mental disorders. 4th ed (DSM-IV). Washington, D.C.: American Psychiatric Association; 1994.

17.

Reilly

Zbrozek

Dukes

. The Validity and Reproducibility of a Work Productivity and Activity Impairment Instrument. Pharmacoeconomics. 1993; 4(5): 353–65.

18.

Finlay

A.Y.

. Current severe psoriasis and the rule of tens. Br J Dermatol. 2005; 152(5): 861–7.

19.

Lebwohl

M.G.

Bachelez

Barker

Patient perspectives in the management of psoriasis: Results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey.

J Am Acad Dermatol. 2014; 70(5): 871–81.e30.